Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Chemokine (C-C motif) ligand 23 (CCL23)
- Target
- CCL23
- Molecular classification
- Chemokine, Cytokine, Endogenous ligand, Secreted protein
01
Overview
Chemokine (C-C motif) ligand 23 (CCL23) is a small, secreted cytokine of the CC chemokine family predominantly expressed in lung, liver, bone marrow, and placenta, as well as by myeloid lineage cells. CCL23 acts as a chemoattractant mainly for resting T cells, monocytes, macrophages, and dendritic cells via the chemokine receptor CCR1, and plays a role in regulating inflammatory responses, suppressing hematopoietic progenitor cell proliferation, and promoting angiogenesis. CCL23 has been linked to a variety of pathological processes including chronic inflammation, tumor microenvironment modulation, and it serves as a biomarker for some cancers like acute myeloid leukemia.
- Other names
- MPIF-1MIP-3Macrophage inflammatory protein 3Myeloid progenitor inhibitory factor 1SCYA23CK-BETA-8CKB-8Ckb-8CKb8CKB8CKb8-1small inducible cytokine subfamily A (Cys-Cys), member 23HMRP-2ACCL23(19-99)CCL23(22-99)CCL23(27-99)CCL23(30-99)
02
Mechanism of action
Potential mechanisms for targeting (experimental/therapeutic): inhibition of CCL23-CCR1 signaling to reduce immune cell recruitment, angiogenesis, or tumor cell migration
03
Biological functions
Immune response (chemotaxis)Regulation of inflammationSuppression of hematopoietic progenitor cell proliferationAngiogenesisMonocyte, T-cell, macrophage, and dendritic cell recruitment
04
Disease associations
Cancer (tumor progression and possibly suppression, depending on context)Inflammation (e.g., chronic rhinosinusitis with nasal polyps, atopic dermatitis)Hematologic malignancies (minimal residual disease monitoring in acute myeloid leukemia)Infection (e.g., trichuriasis, sialadenitis)
05
Safety considerations
Targeting chemokines broadly may impact normal immune and inflammatory responses, potentially increasing infection risk or impairing tissue repair
06
Interacting drugs
No specific drugs directly targeting CCL23 reported; note that small molecule or antibody antagonism to its receptor CCR1 is under investigation in related contexts, but not specific to CCL23
07
Biomarkers
Elevated CCL23 expression is a promising biomarker for monitoring minimal residual disease in acute myeloid leukemia
Beyond the preview
Go deeper on Chemokine (C-C motif) ligand 23 (CCL23).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chemokine (C-C motif) ligand 23 (CCL23).